Chemotherapeutisches Forschungsinstitut Georg-speyer-haus

Drk Blutspendedienst Baden-wurttemberg-hessen Ggmbh

Congcong Zhang

Winfried Wels

Kurt Schönfeld

Torsten Tonn

Manuel Grez

Manuel Kaulich

Anja Waldmann

The present invention pertains to methods and compounds useful in a therapy involving the administration of immune cells to a patient. The method of the invention involves the modification of cells of the immune system with agonists or antagonists of immune regulators such as Interleukin-10 (IL-10) or IL-6, in order to enhance and improve the immunological potential of the immune cells for therapy. Cells modified according to the method of the invention can be administered to a patient to support a treatment of proliferative diseases such as cancer or autoimmune disorders.

Methods and compounds for improved immune cell therapy

The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

CAR-expressing NK-92 cells as cell therapeutic agents

Car-expressing NK-92 cells as cell therapeutic agents

Growing community of inventors

Frankfurt-am-Main, Germany

Congcong Zhang